Irritable Bowel Syndrome (IBS)

Irritable bowel syndrome (IBS). Epidemiology

Newer pharmacologic agents that mediate neurotransmitter activity may prove useful in the treatment of irritable bowel syndrome. Irritable bowel syndrome (IBS) is a chronic disorder characterized by recurrent symptoms of lower abdominal pain with disturbed defecation and bloating….

Corticotropin-Releasing Factor Receptor Antagonists.Chloride-Channel Activators

Corticotropin-Releasing Factor Receptor Antagonists Overview Corticotropin-releasing factor (CRF) is a peptide that functions as a neurotransmitter in the brain. It plays a critical role in coordinating the body’s overall response to stress, and it interacts with two known…

Irritable Bowel Syndrome (IBS): Clinical Presentation

The initial presentation of irritable bowel syndrome (IBS) occurs between the ages of 30 and 50 in over one-half of patients diagnosed with the condition. The classic symptoms reported include abdominal pain, constipation, and/or diarrhea. Patients typically suffer…

Irritable Bowel Syndrome (IBS): Other Agents

Leuprolide acetate, a gonadotropin-releasing hormone (GnRH) analogue, has been investigated as a treatment for irritable bowel syndrome (IBS) because of the predominance of IBS in women and the exacerbation of symptoms reported during menses. Symptoms of abdominal pain,…

Irritable Bowel Syndrome: Emerging Therapies

The investigation of novel compounds for the treatment of irritable bowel syndrome  remains a challenging area of R&D for both the biotechnology and pharmaceutical industries. The problem stems from the lack of understanding of the etiology and pathophysiology…

Antidiarrheals

Overview Diarrhea is one of the most socially restrictive symptoms associated with irritable bowel syndrome. Also, chronic diarrhea carries the possibility of dehydration, which, in severe cases, may lead to a patient being hospitalized for intravenous fluid and…

5-HT Receptor Modulators

Overview Clinical research has shown that modulation of 5-HT3 and 5-HT4 receptors affects visceral pain sensation and intestinal transit. The serotonin (5-HT) receptor modulator drug class has received the majority of irritable bowel syndrome researchers’ attention for nearly…

IBS: Epidemiology

Irritable bowel syndrome (IBS) is common, occurring worldwide in males and females of all age-groups. Prevalence figures vary, owing partly to the lack of definitive diagnostic criteria. On the basis of information compiled from diagnostic and symptom-associated surveys,…

Irritable Bowel Syndrome (IBS): Diagnosis

It is estimated that the typical patient visits an average of three different physicians over a three-year span before receiving the diagnosis of irritable bowel syndrome (IBS). Because there is an absence of distinguishing physical or laboratory markers…

Cilansetron

Cilansetron is a 5-HT receptor modulator being developed by Solvay in the United States and Europe for the treatment of diarrhea-predominant irritable bowel syndrome (D-irritable bowel syndrome) in both men and women. Like the currently marketed alosetron, the…